Welcome to LookChem.com Sign In|Join Free
  • or
4-bromo-1-N-(3-p-toluenesulfonyloxypropyl)-2-nitroimidazole is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

472962-94-0

Post Buying Request

472962-94-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

472962-94-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 472962-94-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,2,9,6 and 2 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 472962-94:
(8*4)+(7*7)+(6*2)+(5*9)+(4*6)+(3*2)+(2*9)+(1*4)=190
190 % 10 = 0
So 472962-94-0 is a valid CAS Registry Number.

472962-94-0Downstream Products

472962-94-0Relevant academic research and scientific papers

Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2- nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent

Yamamoto, Fumihiko,Aoki, Mizuho,Furusawa, Yoshiya,Ando, Koichi,Kuwabara, Yasuo,Masuda, Kouji,Sasaki, Shigeki,Maeda, Minoru

, p. 616 - 621 (2002)

In order to develop new imaging markers for brain hypoxia, 4-bromo-1-(3-fluoropropyl)-2-nitroimidazole (4-BrFPN) was designed based on molecular orbital calculations, synthesized and labeled with fluorine-18 as a lipophilic nitroimidazole analog with a lower energy LUMO orbital than those for fluoromisonidazole (FMISO) and 1-(3-fluoropropyl)-2-nitroimidazole (FPN). In an in vitro radiosensitization study, the sensitizer enhancement ratio for 4-BrFPN was found to be 1.65 at a 1 mM concentration, in comparison to 1.81 for FMISO. The preparation of 18F-labeled 4-BrFPN (4-Br18FPN) was achieved by [18F]fluoride ion displacement reaction of the tosylate precursor, in a reasonable radiochemical yield (33%, not corrected for decay). Metabolites in tumor and muscle extracts from methylcholanthrene-induced fibrosarcoma mice, as well as the tissue distribution of 4-Br18FPN in normal rat, were studied. The initial uptake into rat brain of 4-Br 18FPN was significantly higher relative to 18F-labeled FMISO (18FMISO), followed by a rapid washout from the brain. The tumor uptake of 4-Br18FPN was somewhat enhanced compared to those obtained with 18FMISO and 18F-labeled FPN ( 18FPN), but with lower tumor localization than 18FMISO. Analyses of tumor and muscle extracts showed metabolites remaining base line on the radio-TLC plates, and they were produced to a greater extent in tumor than muscle. The use of two drugs which increase hypoxic cell fraction in tumor, hydralazine or nitro-L-arginine, produced a significant increase in tumor levels of 4-Br18FPN, suggestive of a hypoxic mechanism of accumulation. The results imply that lowering of the LUMO energy of a molecule alone is not sufficient to improve its biodistribution properties for better imaging of regions of hypoxia.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 472962-94-0